Tetraphase Pharmaceuticals (NASDAQ:TTPH) Cut to “Sell” at G.Research

Share on StockTwits

G.Research lowered shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a hold rating to a sell rating in a report issued on Friday, Stock Target Advisor reports.

Several other equities analysts have also commented on the company. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, June 6th. ValuEngine upgraded Tetraphase Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, March 26th. Finally, Gabelli upgraded Tetraphase Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, May 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $21.25.

Tetraphase Pharmaceuticals stock opened at $2.58 on Friday. The stock’s 50 day moving average price is $2.35 and its 200 day moving average price is $2.04. The firm has a market capitalization of $18.88 million, a PE ratio of -0.14 and a beta of 2.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.56 and a current ratio of 3.66. Tetraphase Pharmaceuticals has a one year low of $0.56 and a one year high of $10.60.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.31) EPS for the quarter, topping the consensus estimate of ($1.63) by $0.32. The firm had revenue of $1.76 million for the quarter, compared to analyst estimates of $2.45 million. Tetraphase Pharmaceuticals had a negative return on equity of 210.86% and a negative net margin of 798.18%. On average, analysts forecast that Tetraphase Pharmaceuticals will post -3.95 earnings per share for the current fiscal year.

In other Tetraphase Pharmaceuticals news, major shareholder Jolla Pharmaceutical Co La acquired 234,698 shares of the company’s stock in a transaction on Friday, June 19th. The shares were bought at an average cost of $2.62 per share, for a total transaction of $614,908.76. Following the acquisition, the insider now directly owns 1,085,000 shares of the company’s stock, valued at $2,842,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.70% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sabby Management LLC bought a new stake in shares of Tetraphase Pharmaceuticals in the 1st quarter valued at approximately $854,000. Renaissance Technologies LLC increased its holdings in shares of Tetraphase Pharmaceuticals by 38.2% in the 4th quarter. Renaissance Technologies LLC now owns 224,940 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 62,125 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Tetraphase Pharmaceuticals by 20.3% in the 1st quarter. BlackRock Inc. now owns 69,799 shares of the biopharmaceutical company’s stock valued at $89,000 after acquiring an additional 11,757 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Tetraphase Pharmaceuticals during the 4th quarter worth $174,000. Finally, Geode Capital Management LLC grew its stake in Tetraphase Pharmaceuticals by 52.0% during the 4th quarter. Geode Capital Management LLC now owns 30,826 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 10,541 shares during the last quarter. Institutional investors and hedge funds own 42.29% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

See Also: Are analyst ratings accurate?

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.